1-3 of 3
Marcus Matthias Schittenhelm
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A New Class of Synthetic Type-B Polycyclic Polyprenylated Acylphloroglucinols (PPAP-B) Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia (AML)

Leonie Elisabeth Kampa, Anton Bleisch, Philipp Peslalz, Marcus Matthias Schittenhelm, Bernd Plietker, Kerstin Maria Kampa-Schittenhelm
Journal: Blood
Blood (2023) 142 (Supplement 1): 4157.
https://doi.org/10.1182/blood-2023-189692
Published: 2023
Journal Articles

Overexpression of Oncogenic Inhibitory-ASPP (inhibitor of apoptosis stimulating protein of p53) Results in Therapy Resistance and Adverse Outcome in AML

Marcus Matthias Schittenhelm, Mihada Bajrami Saipi, Gunnar Blumenstock, Peter JM Valk, Balazs Györffy, Kerstin Maria Kampa-Schittenhelm
Journal: Blood
Blood (2022) 140 (Supplement 1): 3433–3434.
https://doi.org/10.1182/blood-2022-170405
Published: 2022
Journal Articles

Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All- Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Michael Lübbert, Claudia Schmoor, Tobias Berg, Michael Kruszewski, Marcus Matthias Schittenhelm, Katharina Götze, Caroline Pabst, Andrea Kündgen, Tobias Ma, Anna Frey, Kevin Moschallski, Usama-Ur Rehman, Johannes Jung, Justus Duyster, Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina
Journal: Blood
Blood (2022) 140 (Supplement 1): 9087–9088.
https://doi.org/10.1182/blood-2022-159471
Published: 2022